Scott Tilden

ORCID: 0000-0002-6241-5506
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Microtubule and mitosis dynamics
  • Influenza Virus Research Studies
  • interferon and immune responses
  • Tryptophan and brain disorders
  • Immunotherapy and Immune Responses
  • Treatment of Major Depression
  • Hepatitis C virus research
  • RNA Interference and Gene Delivery
  • Stress Responses and Cortisol
  • Graphene and Nanomaterials Applications
  • Nanoparticle-Based Drug Delivery
  • 14-3-3 protein interactions
  • Advanced biosensing and bioanalysis techniques
  • Cancer Immunotherapy and Biomarkers
  • HIV/AIDS Research and Interventions
  • Immune Cell Function and Interaction
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • Virus-based gene therapy research
  • Protein Structure and Dynamics
  • Nanoparticles: synthesis and applications
  • Photosynthetic Processes and Mechanisms
  • Extracellular vesicles in disease

University of Montana
2023-2024

University of Colorado Anschutz Medical Campus
2019-2024

The Ohio State University
2024

University of Colorado System
2018

University of Colorado Boulder
2018

Center for Neurosciences
2016

In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting several approved drugs multiple promising candidates clinical trials. Regulatory agencies such as the Food Drug Administration European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly context of liposomes lipid-based carriers. Even with achieved, it is clear that many barriers must still be overcome...

10.1021/acsnano.4c00182 article EN ACS Nano 2024-05-20

Recent interest in the antidepressant and anti-stress effects of subanesthetic doses ketamine, an NMDA receptor antagonist, has identified mechanisms whereby ketamine reverses effect stress, but little is known regarding prophylactic might have on future stressors. Here we investigate against neurochemical behavioral changes that follow inescapable, uncontrollable tail shocks (ISs) Sprague Dawley rats. IS induces increased anxiety, which dependent activation serotonergic (5-HT) dorsal raphe...

10.1523/jneurosci.3114-15.2016 article EN cc-by-nc-sa Journal of Neuroscience 2016-01-06

Abstract Stress is a potent etiological factor in the onset of major depressive disorder and posttraumatic stress (PTSD). Therefore, significant efforts have been made to identify factors that produce resilience outcomes later stressor, hopes preventing untoward clinical outcomes. The NMDA receptor antagonist ketamine has recently emerged as prophylactic capable neurochemical behavioral future stressor. Despite promising results preclinical studies performed male rats, effects proactive...

10.1523/eneuro.0025-18.2018 article EN cc-by-nc-sa eNeuro 2018-01-01

Tenofovir monoester is a relatively lipophilic intermediate formed during the hydrolysis of tenofovir disoproxil to tenofovir. Its clinical pharmacokinetic profile and influence on cellular pharmacology diphosphate have not been reported.Plasma, PBMC dried blood spots (DBS) were obtained from HIV-uninfected adults participating in randomized, cross-over bioequivalence study single-dose fumarate (TDF)/emtricitabine unencapsulated or encapsulated with Proteus® ingestible sensor. Plasma...

10.1093/jac/dkz187 article EN Journal of Antimicrobial Chemotherapy 2019-04-11

<title>Abstract</title> Immune reactions to nanomedicines can be detrimental the patient and compromise efficacy. However, our recent study characterizing effects of a type III interferon (IFN-λ) response lipid nanoparticles complexed with nucleic acids (lipoplexes) suggests that an IFN-λ pretreatment increase efficacy chemotherapeutic nanomedicines. In this we sought clarify which cell type(s) are capable producing in lipoplexes how propagated. Additionally, demonstrate is also altering...

10.21203/rs.3.rs-4289446/v1 preprint EN cc-by Research Square (Research Square) 2024-05-03
Coming Soon ...